New DNA-Protecting Protein Could Hold Key to Destroying Cancer Cells

Research Advances /

Researchers have identified KCTD10 as a key “traffic controller” for DNA, coordinating the essential processes of replication and transcription to maintain genomic stability. During cell division, replication machinery rapidly duplicates DNA, while transcription machinery reads it to produce RNA. Collisions between these processes can cause DNA damage, double-strand breaks, and mutations that drive cancer. KCTD10 […]

New DNA-Protecting Protein Could Hold Key to Destroying Cancer Cells Read More »

Dual Immunotherapy Approach Eradicates Liver Metastases in Advanced Colon Cancer

Immunotherapy /

Advanced colon cancer is a growing cause of cancer-related death among young American men, particularly when it spreads to the liver. Liver metastases are highly resistant to current immunotherapies and often recur even after surgery, creating a critical need for new treatment strategies. A recent study identified a novel dual-immunotherapy approach that reprograms the liver

Dual Immunotherapy Approach Eradicates Liver Metastases in Advanced Colon Cancer Read More »

Calquence Triplet Achieves 92% Complete Response Rate in Frontline Follicular Lymphoma

Treatment /

A phase 2 study published in Nature Communications (NCT04404088) showed that the frontline, chemotherapy-free combination of acalabrutinib (Calquence), lenalidomide (Revlimid), and rituximab (Rituxan) was both safe and effective for patients with advanced-stage, high-tumor-burden follicular lymphoma. Among 24 patients with a median follow-up of 43 months, the best complete response rate reached 92% after just six treatment

Calquence Triplet Achieves 92% Complete Response Rate in Frontline Follicular Lymphoma Read More »

Gene Therapy Destroys KSHV-Linked Cancer Cells

Precision Medicine /

A new, highly targeted gene therapy developed by UC Davis scientists, shows promise for treating cancers caused by the Kaposi’s sarcoma-associated herpesvirus (KSHV), such as Kaposi’s sarcoma. The preclinical study, published in Molecular Therapy Oncology, utilizes a harmless adeno-associated virus (AAV) to deliver a “Trojan horse” gene into KSHV-infected cancer cells. This therapy is activated

Gene Therapy Destroys KSHV-Linked Cancer Cells Read More »

Rucaparib Maintenance Therapy Significantly Extends Survival in Recurrent Endometrial Cancer

Treatment /

Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) greatly improved progression-free survival in patients with recurrent or metastatic endometrial cancer after first- or second-line chemotherapy, according to a phase 2 study. Patients receiving rucaparib had a median progression-free survival of 28.1 months compared with 8.7 months for those given a placebo, representing a 55% lower

Rucaparib Maintenance Therapy Significantly Extends Survival in Recurrent Endometrial Cancer Read More »

Blood Test Detects HPV-Linked Head and Neck Cancer a Decade Before Symptoms

Diagnostics /

A new study from Mass General Brigham published in the Journal of the National Cancer Institute reports a major advance in early detection of HPV-linked head and neck cancer. The new blood test, called HPV-DeepSeek, uses whole-genome sequencing to find tiny fragments of HPV DNA in the bloodstream. It was able to detect cancer up to

Blood Test Detects HPV-Linked Head and Neck Cancer a Decade Before Symptoms Read More »

OST-HER2 Immunotherapy Shows 75% Two-Year Survival in Recurrent Pulmonary Osteosarcoma

Immunotherapy /

The off-the-shelf immunotherapy OST-HER2 (OST31-164) demonstrated impressive 2-year overall survival results in a phase 2b trial for patients with recurrent, fully resected pulmonary metastatic osteosarcoma. The 2-year overall survival rate reached 75% among evaluable patients (n=36), significantly higher than the historical control rate of 40% (P<.0001). Patients who achieved an event-free survival (EFS) of at

OST-HER2 Immunotherapy Shows 75% Two-Year Survival in Recurrent Pulmonary Osteosarcoma Read More »

Abemaciclib Delivers 84% Response Rate in Kaposi Sarcoma, Including HIV-Positive Patients

Treatment /

Abemaciclib Shows High Efficacy in Kaposi Sarcoma, Including HIV-Associated Cases A phase 1/2 trial (NCT04941274) presented at the 2025 ASCO Annual Meeting found that the CDK4/6 inhibitor abemaciclib (Verzenio) was well-tolerated and demonstrated strong antitumor activity in both HIV-associated and HIV-negative Kaposi sarcoma. Among 31 efficacy-evaluable patients, the overall response rate (ORR) was 84%. Patients

Abemaciclib Delivers 84% Response Rate in Kaposi Sarcoma, Including HIV-Positive Patients Read More »

New Liquid Biopsies and AI-Powered Tests Promise a Future of Earlier Colorectal Cancer Detection

Technology Innovation /

Colorectal cancer (CRC) is rising worldwide, particularly early-onset cases, creating an urgent need for earlier detection to improve survival. Traditional screening methods have limitations: colonoscopy is invasive and resource-intensive, while stool-based tests like FIT often miss early-stage cancers. CRC arises from adenomas through cumulative mutations (e.g., APC, KRAS, TP53) and exhibits molecular heterogeneity, classified into

New Liquid Biopsies and AI-Powered Tests Promise a Future of Earlier Colorectal Cancer Detection Read More »

Immunotherapy Combination Shows Durable 5-Year Survival in Advanced Liver Cancer

Immunotherapy /

The HIMALAYA phase III study demonstrated that the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) provides a sustained and clinically meaningful overall survival (OS) benefit compared to sorafenib for patients with previously untreated, unresectable hepatocellular carcinoma (uHCC). The 5-year follow-up data established a new survival benchmark in uHCC, showing a 60-month (5-year) OS rate of 19.6% for STRIDE versus

Immunotherapy Combination Shows Durable 5-Year Survival in Advanced Liver Cancer Read More »